Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by wildbird1on Aug 28, 2022 11:08am
782 Views
Post# 34925228

Next batch of CR% results????

Next batch of CR% results????We don't know what the next batch of CR%(Complete Response) will be.

But we know this...
In the June 24,2022 PressRelease, Dr. Arkady Mandel said" The success in the Phase 1b NMIBC clinical study has led to the impressive preliminary results demonstrated in the Phase 11 NMIBC clinical study, focused primarily on efficacy and secondary on safety. In the future, I foresee great potential for Theralase Anti-cancer therapy (ACT) to deliver a safe and effective anti-cancer treatment for numerous cancer indications with high unmet needs".

Everyday we are getting closer & closer to these impressive results that will get TLT BTD(Break Through Designation).

Note1) Dr.Mandel is a scientist (Chief Scientific Officer of TLT), scientists have a tendency to be careful and more concervative when making predictions.

Note 2) Big Pharma are going to love "Numerous cancer indications with unmet needs"

Be ready for it, in the near future, events could unfold rapidly.





<< Previous
Bullboard Posts
Next >>